Suchergebnisse - "Robak, Tadeusz"

PubPharm (786)

1

Successful treatment with cladribine in a patient with Rosai-Dorfman disease complicated by severe, prolonged marrow aplasia

enthalten in: Leukemia & lymphoma | 2024

von Robak, T. | Braun, M. | Guminska, A. | +2

2

Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma

enthalten in: Expert opinion on drug metabolism & toxicology | 2024

von Wolska-Washer, A. | Robak, P. | Witkowska, M. | +1

3

Thrombopoietin receptor agonist and rituximab combination therapy in patients with refractory primary immune thrombocytopenia

enthalten in: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis | 2024

von Witkowski, M. | Ryżewska, W. | Robak, T.

4

Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies : post-hoc analysis of a large clinical trial safety database

enthalten in: Haematologica | 2024

von Brown, J. | Ghia, P. | Jurczak, W. | +14

5

Primary Cutaneous CD30 positive Lymphoproliferative Disorders—Current Therapeutic Approach with Focus on Brentuximab Vedotin

enthalten in: Preprints.org | 2024

von Stein, T. | Robak, T. | Biernat, W. | +1

6

Primary Cutaneous CD30-Positive Lymphoproliferative Disorders-Current Therapeutic Approaches with a Focus on Brentuximab Vedotin

enthalten in: Journal of clinical medicine | 2024

von Stein, T. | Robak, T. | Biernat, W. | +1

7

Treatment of Double-Refractory Chronic Lymphocytic Leukemia-An Unmet Clinical Need

enthalten in: International journal of molecular sciences | 2024

von Zygmunciak, P. | Robak, T. | Puła, B.

8

Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors

enthalten in: Haematologica | 2024

von Le Gouill, S. | Długosz-Danecka, M. | Rule, S. | +15

9

Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma patients treated with bortezomib-based regimens - pilot study

enthalten in: Leukemia & lymphoma | 2024

von Puła, A. | Robak, T. | Dróżdż, I. | +4

10

Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW) : 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2023

von Niemann, C. | Munir, T. | Moreno, C. | +21

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[79]